Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients

Psychiatry Research

Volumn 229, Issue 1-2, 2015, Pages 200-205

  Sertan Copoglu, U ^a   Virit, Osman ^b   Hanifi Kokacya, M ^a   Orkmez, Mustafa ^c   Bulbul, Feridun ^b   Binnur Erbagci, A ^b   Semiz, Murat ^d   Alpak, Gokay ^b   Unal, Ahmet ^b   Ari, Mustafa ^a   Savas, Haluk A ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c Sehit Kamil State Hospital   (Turkey)

^d GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

8 hydroxydeoxyguanosine; Oxidative DNA damage; Oxidative stress; Schizophrenia; Symptomatic remission

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; OXIDIZING AGENT;

ADULT; ARTICLE; BLOOD BIOCHEMISTRY; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE DURATION; DNA DAMAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OXIDATIVE STRESS; OXIDATIVE STRESS INDEX; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; TOTAL ANTIOXIDANT STATUS; TOTAL OXIDANT STATUS; BLOOD; CROSS-SECTIONAL STUDY; MIDDLE AGED; PHYSIOLOGY;

ADULT; BIOMARKERS; CROSS-SECTIONAL STUDIES; DNA DAMAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; REMISSION INDUCTION; SCHIZOPHRENIA;

EID: 84939467631     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.036     Document Type: Article

References (57)

1. Aizenman E., Stout A.K., Hartnett K.A., Dineley K.E., McLaughlin B., Reynolds I.J. Induction of neuronal apoptosis by thiol oxidation. J. Neurochem. 2000, 75(5):1878-1888.
2. Akyol Ö., Herken H., Uz E., Fadillioglu E., Ünal S., Sögüt S., Özyurt H., Savaş H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2002, 26(5):995-1005.
3. American Psychiatric, A., 2000. Diagnostic and statistical manual of mental disorders: DSM-IV-TR®. American Psychiatric Pub.
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
5. Ben Othmen L., Mechri A., Fendri C., Bost M., Chazot G., Gaha L., Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32(1):155-159.
6. Bitanihirwe B.K.Y., Woo T.-U.W. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35(3):878-893.
7. Bošković M., Vovk T., Plesničar B.K., Grabnar I. Oxidative stress in schizophrenia. Curr. Neuropharmacol. 2011, 9(2):301.
8. Bredesen D.E. Neural apoptosis. Ann. Neurol. 1995, 38(6):839-851.
9. Cardozo-Pelaez F., Brooks P.J., Stedeford T., Song S., Sanchez-Ramos J. DNA damage, repair, and antioxidant systems in brain regions: a correlative study. Free Radic. Biol. Med. 2000, 28(5):779-785.
10. Catts V.S., Catts S.V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?. Schizophr. Res. 2000, 41(3):405-415.
11. Cooke M.S., Evans M.D., Dizdaroglu M., Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003, 17(10):1195-1214.
12. Crawford D.R., Suzuki T., Sesay J., Davies K.J. Analysis of gene expression following oxidative stress. Methods Mol. Biol. 2002, 196:155-162.
13. De Bont R., Van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 2004, 19(3):169-185.
14. Devi P.U., Devipriya D., Murugan S., Selvi S., Suja S., Chinnaswamy P. Evaluation of plasma total antioxidant response and total peroxides in different symptoms of schizophrenia patients. Int. J. Biol. Chem. 2008, 2:1.
15. Dragunow M., Faull R.L.M., Lawlor P., Beilharz E.J., Singleton K., Walker E.B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995, 6(7):1053-1057.
16. Emiliani F.E., Sedlak T.W., Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr. Opin. Psychiatry 2014, 27(3):185-190.
17. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin.l Biochem. 2004, 37(2):112-119.
18. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 2005, 38(12):1103-1111.
19. Esteve J., Mompo J., De La Asuncion J.G., Sastre J., Asensi M., Boix J., Vina J., Vina J., Pallardo F. Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro. FASEB J. 1999, 13(9):1055-1064.
20. Evan G., Littlewood T. A matter of life and cell death. Science 1998, 281(5381):1317-1322.
21. Friedberg E.C., McDaniel L.D., Schultz R.A. The role of endogenous and exogenous DNA damage and mutagenesis. Curr. Opin. Genet. Dev. 2004, 14(1):5-10.
22. Gasso P., Mas S., Molina O., Lafuente A., Bernardo M., Parellada E. Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naive first-episode schizophrenia patients. J Psychiatr. Res. 2014, 48(1):94-101.
23. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006, 81(1):47-63.
24. Grignon S., Chianetta J.M. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(2):365-369.
25. Guy, W., 1976. Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW Publ No. ADM 76-338, pp. 218-222.
26. Helbock H.J., Beckman K.B., Ames B.N. 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol. 1999, 300:156.
27. Helsinki, H.D., 2007. World Medical Association Declaration of Helsinki.
28. Herken H., Uz E., Özyurt H., Sögüt S., Virit O., Akvol Ö. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 2001, 6(1):66-73.
29. Hu C.-W., Chao M.-R., Sie C.-H. Urinary analysis of 8-oxo-7, 8-dihydroguanine and 8-oxo-7, 8-dihydro-2'-deoxyguanosine by isotope-dilution LC-MS/MS with automated solid-phase extraction: study of 8-oxo-7, 8-dihydroguanine stability. Free Radic. Biol. Med. 2010, 48(1):89-97.
30. Kagan V.E., Gleiss B., Tyurina Y.Y., Tyurin V.A., Elenström-Magnusson C., Liu S.-X., Serinkan F.B., Arroyo A., Chandra J., Orrenius S. A role for oxidative stress in apoptosis: oxidation and externalization of phosphatidylserine is required for macrophage clearance of cells undergoing Fas-mediated apoptosis. J. Immunol. 2002, 169(1):487-499.
31. Kay S.R., Flszbein A., Opfer L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261.
32. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., Ruther E., Emrich H.M., Schneider U., Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatry Clin. Neurosci. 2005, 17(2):227-231.
33. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88(3):323-331.
34. Li X.F., Zheng Y.L., Xiu M.H., Chen D.C., Kosten T.R., Zhang X.Y. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35(4):1064-1067.
35. Lovell M.A., Markesbery W.R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007, 35(22):7497-7504.
36. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biolo. Psychiatry 1998, 43(9):674-679.
37. McCreadie R.G., MacDonald E., Wiles D., Campbell G., Paterson J.R. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br. J. Psychiatry 1995, 167(5):610-617.
38. Mecocci P., MacGarvey U., Kaufman A.E., Koontz D., Shoffner J.M., Wallace D.C., Beal M.F. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 1993, 34(4):609-616.
39. Nishioka N., Arnold S.E. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry 2004, 12(2):167-175.
40. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003, 37(1):43-51.
41. Pazvantoglu O., Selek S., Okay I.T., Sengul C., Karabekiroglu K., Dilbaz N., Erel Ö. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin. Neurosci. 2009, 63(5):693-700.
42. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007, 41(5):372-386.
43. Prabhulkar S., Li C.-Z. Assessment of oxidative DNA damage and repair at single cellular level via real-time monitoring of 8-OHdG biomarker. Biosens. Bioelectron. 2010, 26(4):1743-1749.
44. Sen N., Hara M.R., Kornberg M.D., Cascio M.B., Bae B.I., Shahani N., Thomas B., Dawson T.M., Dawson V.L., Snyder S.H., Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 2008, 10(7):866-873.
45. Shahani N., Sawa A. Protein S-nitrosylation: role for nitric oxide signaling in neuronal death. Biochim. Biophys. Acta 2012, 1820(6):736-742.
46. Sharpe M.A., Robb S.J., Clark J.B. Nitric oxide and Fenton/Haber-Weiss chemistry: nitric oxide is a potent antioxidant at physiological concentrations. J. Neurochem. 2003, 87(2):386-394.
47. Singh O.P., Chakraborty I., Dasgupta A., Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J. Psychiatry 2008, 50(3):171-176.
48. Stadtman E.R. Protein oxidation and aging. Science 1992, 257(5074):1220-1224.
49. Tang D.G., La E., Kern J., Kehrer J.P. Fatty acid oxidation and signaling in apoptosis. Biol. Chem. 2002, 383(3-4):425-442.
50. Trinei M., Giorgio M., Cicalese A., Barozzi S., Ventura A., Migliaccio E., Milia E., Padura I.M., Raker V.A., Maccarana M. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 2002, 21(24):3872-3878.
51. Ustundag B., Atmaca M., Kirtas O., Selek S., Metin K., Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin. Neurosci. 2006, 60(4):458-464.
52. Virit O., Altindag A., Yumru M., Dalkilic A., Savas H.A., Selek S., Erel O., Herken H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009, 60(2):87-93.
53. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 1998, 32(1):1-8.
54. Yao J.K., Reddy R.D., van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol. Psychiatry 1999, 45(11):1512-1515.
55. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci. China Life Sci. 2010, 53(1):112-124.
56. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81(2-3):291-300.
57. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J. Clin. Psychopharmacol. 2003, 23(2):128-131.